Company Overview
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome (ARDS). It is also developing MiNK-215, an IL-15 armored tumor stromal targeting the FAP-CAR-iNKT program to treat solid tumors and inflammation; and MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen for autoimmune diseases, including in graft-versus-host disease prevention. The company has collaborations with Autonomous Therapeutics to target and treat metastatic tumors; ImmunoScape, Inc. to discover and develop T-cell receptor therapies against targets in solid tumors; and C-Further for the development of PRAME-targeted iNKT cell therapy for pediatric cancers. The company was formerly known as AgenTus Therapeutics, Inc. and changed its name to MiNK Therapeutics, Inc. in June 2021. The company was incorporated in 2017 and is based in New York, New York.
Why Investors Should Care
Generates a return on equity of 87.8%, reflecting efficient use of shareholder capital.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -34.57% |
| 6 Months: | +9.57% |
| 3 Months: | +0.97% |
| 1 Month: | +4.57% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)51.33 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 87.8%.
CONS
- Trading 34.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | INKT MiNK Therapeutics, Inc. PHARMA | 11.45 | -4.83 | $58.43M | 0.00% | - | 87.82% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.53M | 3.69M | 2.99M | 3.28M | 2.88M |
| Operating Income | - | - | -5.92M | -3.01M | -5.61M | -13.38M | -7.37M | -7.70M | -7.99M | -5.85M | -6.34M | -5.22M | -3.83M | -3.07M | -1.88M | - | -2.53M | -3.69M | -2.99M | -3.28M | -2.88M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.48M | -3.64M | -2.95M | -3.24M | -2.85M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.77M | -4.24M | -2.89M | -2.60M | -2.74M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -4.39M | -4.27M | -6.04M | -3.85M | -6.34M | -14.27M | -7.78M | -6.11M | -6.33M | -5.69M | -6.20M | -5.12M | -3.81M | -2.70M | -1.81M | - | -2.77M | -4.24M | -2.89M | -2.60M | -2.74M |
| Diluted EPS | - | - | - | - | -0.26 | -0.59 | -0.23 | -0.18 | -0.19 | -0.17 | -0.18 | -0.15 | -1.10 | -0.73 | -0.46 | - | -0.70 | -1.06 | -0.65 | - | -0.57 |
| R&D Expense | - | - | 2.50M | 3.10M | 3.58M | 3.33M | 5.28M | 5.88M | 6.15M | 4.19M | 4.56M | 3.43M | 2.55M | 1.84M | 540.64K | - | 1.26M | 1.84M | 1.14M | - | 1.20M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Income | -14.64M | -28.36M | -30.95M | -22.92M | -11.29M | -12.64M |
| Net Income | -16.24M | -30.21M | -27.99M | -22.46M | -10.78M | -12.49M |
| Diluted EPS | - | -1.16 | -0.83 | -6.54 | -2.86 | -2.93 |
| R&D Expense | 9.51M | 13.97M | 23.12M | 15.49M | 6.34M | 5.76M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 4.56M | 40.24M | 21.47M | 4.55M | 5.72M | 14.24M |
| Total Equity | -36.33M | -53.87M | 23.78M | -401.30K | -18.06M | -19.59M | -14.23M |
| Cash & Equivalents | - | - | 38.89M | 19.64M | 3.37M | 4.58M | 13.36M |
| Current Liabilities | - | 14.22M | 16.47M | 12.68M | 11.40M | 6.96M | 13.03M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -8.34M | -12.83M | -18.87M | -15.76M | -9.56M | -5.93M |
| Investing Cash Flow | -95.21K | -248.98K | -250.05K | -73.56K | - | - |
| Financing Cash Flow | 11.11M | 49.26M | -155.60K | -407.17K | 10.82M | 14.72M |
| Capital Expenditure | -95.21K | -248.98K | -250.05K | -73.56K | - | - |
| Free Cash Flow | -8.43M | -13.08M | -19.12M | -15.84M | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | 30.1% | -127.1% | 6,975.1% | 124.4% | 55.1% | 87.8% |
| ROCE % | 151.4% | -119.3% | -352.2% | 334.6% | 911.2% | -1,047.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 1.35% | 68.66K | $827.35K |
| 2 | DnB Asset Management AS | 1.08% | 55.14K | $664.46K |
| 3 | Longbow Finance Sa | 0.33% | 16.67K | $200.84K |
| 4 | Geode Capital Management, LLC | 0.31% | 15.57K | $187.65K |
| 5 | Citadel Advisors Llc | 0.30% | 15.44K | $186.05K |
| 6 | Blackrock Inc. | 0.26% | 13.38K | $161.25K |
| 7 | Vanguard Fiduciary Trust Co | 0.16% | 8.29K | $99.86K |
| 8 | UBS Group AG | 0.10% | 4.88K | $58.86K |
| 9 | US BANCORP \DE\ | 0.04% | 2.00K | $24.04K |
| 10 | Steward Partners Investment Advisory, LLC | 0.04% | 2.00K | $24.10K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for INKT
Insider at MiNK Therapeutics (NASDAQ: INKT) reports new stock transactions - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxNY1U5endOcC1jaE9oZHRUdFVlS21ISmduMkdIbEVXcTV0M3c2NXhzbUpOdkRZVVFPczE3dzF1empjT09EVFl5WHlkNjdkbEYwYjhZR0pvcjgxcVpQV2htTWJESVRTREJoNkhna01JSVoyYldzZUxGREwyTW9kMERDakhNRE1RTEhJT2t2WW…
Why (INKT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxOTGZKWFVEV0Z2cDFEVGJER3pIeWVFYkY4SmVoelEwb3ZKYmVLWExmZVJBR2cxdUlIYWpOTzd6ZVFSWjNzSWwzdk5SX1JJYUppRFUwbzhHXzlYTHpycU9qSkhqMlpCaXBtVFpSWXh1TEdCRWw2QlhJTTljaVpLMUo5dDVxb0E2Znh5WG5zUl…
Why Did INKT Stock Jump 30% Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxPSUh4dm5aem9FZk5jVXVERW15Q25lamtqcXVzclZJUFNxeXhIZDF1QUNpSGZpQUFhRkxaZ0Uxd0szVXNILTNFUWhIYWVPRXAyYUJteGtDd2ROdDg3R0hNbnZFbDR4ajJ0ZkozSWhfOTlHTXRKZXc3X1E2SVAyRmpCWFNROHlqLW9TSEJ5Rn…
INKT - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE5qUGtxV1JYeHJPV044YXhqNHVVZmdELTVaZWNxWTVNbGF0TGVYS3hpS0JVc1R2UHFiXzhJVFBsVjhPZWp0a2c?oc=5" target="_blank">INKT</a> <font color="#6f6f6f">Finviz</font>…
INKT Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9fR0hSOGNKWnNPeXhqcG4zN1hvNkVxbEJad1VQM3UtX3BlSWhvbDhLTGd3cnl6VGY3NlB5NzJ2R1pqemZmbzRuLVNrQUxZd3VJYllQdFJqVmE2cm5HZF9kVV9WTkpDRkhsTFJ0YlR2VVVYamtwQ01mWmV3?oc=5" target="_blank">INK…
Should I buy MiNK Therapeutics, Inc. (INKT) - Zacks Investment Research
<a href="https://news.google.com/rss/articles/CBMibEFVX3lxTE85dkN1WUU2aEZoUWE5VU1obk1wbGZyc01VcFU0TUdjNXI5OXRFaVY3cERTXzJtQVdpU1RoR3lfdFM0dDh1TUpoM3l5OFpvMWZqdXB6MkxEa29LUDFGdUc5U1k3UTBESG5NRkY0Vg?oc=5" target="_blank">Should I buy MiNK The…
INKT — Frequently Asked Questions
What is the current share price of MiNK Therapeutics, Inc. (INKT)?
As of 2026-09-19 21:16 PDT, MiNK Therapeutics, Inc. (INKT) trades at $11.45 on NasdaqCM. Its 52-week range is $8.56 to $17.50.
What is the market capitalisation of INKT?
MiNK Therapeutics, Inc. (INKT) has a market capitalisation of $58.43M on NasdaqCM.
What is the P/E ratio of INKT?
INKT trades at a trailing price-to-earnings (P/E) ratio of -4.83. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -4.38.
What is the return on equity (ROE) of INKT?
INKT has a return on equity (ROE) of 87.82%.
Is INKT a good stock to buy?
This page provides a data-driven analysis of MiNK Therapeutics, Inc. (INKT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.